

# Hie-Won Hann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2577480/publications.pdf>

Version: 2024-02-01

31  
papers

709  
citations

623574

14  
h-index

552653

26  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1083  
citing authors

#	ARTICLE	IF	CITATIONS
1	Urine DNA biomarkers for hepatocellular carcinoma screening. British Journal of Cancer, 2022, 126, 1432-1438.	2.9	15
2	Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress. International Journal of Molecular Sciences, 2022, 23, 3917.	1.8	5
3	Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level. Viruses, 2022, 14, 775.	1.5	16
4	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. Journal of Hepatology, 2022, 77, 642-652.	1.8	17
5	First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alafenamide. Hepatology Communications, 2022, 6, 1881-1894.	2.0	7
6	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. Journal of Hepatology, 2022, 77, 1265-1275.	1.8	21
7	Hepatitis B-related hepatocellular carcinoma and stress: untangling the host immune response from clinical outcomes. Hepatic Oncology, 2021, 8, HEP35.	4.2	4
8	Gender Disparity in Host Responses to Hepatitis B-Related Hepatocellular Carcinoma: A Case Series. Vaccines, 2021, 9, 838.	2.1	8
9	Detection of Hepatitis B Virus Host Junction Sequences in Urine of Infected Patients. Hepatology Communications, 2021, 5, 1649-1659.	2.0	11
10	Vagaries of the Host Response to Chronic Hepatitis B Virus Infection: What is the Ultimate Outcome of So-called "Asymptomatic HBV Carriers" Observed Over Several Decades?. Journal of Immunological Sciences, 2021, 5, 15-20.	0.5	3
11	Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clinical Gastroenterology and Hepatology, 2020, 18, 457-467.e21.	2.4	56
12	Vagaries of the Host Response in the Development of Hepatitis B-related Hepatocellular Carcinoma: A Case Series. Current Cancer Therapy Reviews, 2020, 16, 253-258.	0.2	5
13	IDDF2020-ABS-0058...48-week safety and efficacy of switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) in chronic HBV asian patients with TDF risk factors (RF). , 2020, , .		0
14	"The host's role in hepatocellular carcinoma development: A case of regression from probable malignancy to a benign lesion". Integrative Cancer Science and Therapeutics, 2019, 6, .	0.1	3
15	Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World Journal of Hepatology, 2019, 11, 65-73.	0.8	12
16	Ferritin level prospectively predicts hepatocarcinogenesis in patients with chronic hepatitis B virus infection. Oncology Letters, 2018, 16, 3499-3508.	0.8	15
17	Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure. Diseases (Basel, Switzerland), 2018, 6, 27.	1.0	25
18	Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients. Carcinogenesis, 2017, 38, 439-446.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. <i>Journal of Hepatology</i> , 2017, 66, 11-18.	1.8	52
20	Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma. <i>Hepatoma Research</i> , 2017, 3, 105.	0.6	47
21	Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection. <i>Scientific Reports</i> , 2016, 6, 23992.	1.6	66
22	A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. <i>Cancer Medicine</i> , 2014, 3, 390-396.	1.3	35
23	HBV-related health behaviors in a socio-cultural context: Perspectives from Khmers and Koreans. <i>Applied Nursing Research</i> , 2014, 27, 127-132.	1.0	14
24	Then and now: The progress in hepatitis B treatment over the past 20 years. <i>World Journal of Gastroenterology</i> , 2014, 20, 401.	1.4	47
25	Comprehensive Analysis of Common Serum Liver Enzymes as Prospective Predictors of Hepatocellular Carcinoma in HBV Patients. <i>PLoS ONE</i> , 2012, 7, e47687.	1.1	67
26	Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated. <i>International Journal of Cancer</i> , 2011, 128, 739-742.	2.3	18
27	Analysis of GP73 in patients with HCC as a function of anti-cancer treatment. <i>Cancer Biomarkers</i> , 2011, 7, 269-273.	0.8	16
28	Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2243-2249.	0.9	9
29	Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). <i>Hepatology International</i> , 2008, 2, 244-249.	1.9	39
30	A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B. <i>Hepatology International</i> , 2008, 2, 440-456.	1.9	14
31	Depression in Korean Immigrants With Hepatitis B and Related Liver Diseases. <i>Psychosomatics</i> , 2000, 41, 472-480.	2.5	56